Gastric Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 21, 2005; 11(35): 5433-5437
Published online Sep 21, 2005. doi: 10.3748/wjg.v11.i35.5433
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Inhibition of allitridi on MGC803 and SGC7901. Allitridi (3, 6, or 9 μg/mL) inhibited cell growth in a dose-dependent manner.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Morphological changes of allitridi-treated MGC803 and SGC7901 cells under electron microscope (×5 000). A: MGC803 control cells; B and C: 12 μg/mL allitridi-induced MGC803 cells; D: SGC7901 control cells; E and F: 12 μg/mL allitridi-induced SGC7901 cells.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Cell cycle changes of MGC803 cells (A1-4) and SGC 7901 cells (B1-4) 24 h after allitridi treatment. A1, B1: Control cells; A2, B2: allitridi 3 μg/mL; A3, B3: allitridi 6 μg/mL; A4, B4: allitridi 9 μg/mL.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Expression of p21 in MGC803 and SGC7901 cells after being treated with allitridi (SP ×400). A: Control of MGC803 cells; B: treated MGC803 cells with 6 μg/mL allitridi; C: control of SGC7901 cells; D: treated SGC7901 cells with 6 μg/mL allitridi.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Effect of allitridi treatment on p21WAF1 mRNA expression in MGC803 cells (A) and SGC7901 cells (B). M: DNA markers: 1: control cells; 2: 6 mg/mL allitridi; 3: 9 mg/mL allitridi.